DK1113015T3 - Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister - Google Patents
Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonisterInfo
- Publication number
- DK1113015T3 DK1113015T3 DK00311130T DK00311130T DK1113015T3 DK 1113015 T3 DK1113015 T3 DK 1113015T3 DK 00311130 T DK00311130 T DK 00311130T DK 00311130 T DK00311130 T DK 00311130T DK 1113015 T3 DK1113015 T3 DK 1113015T3
- Authority
- DK
- Denmark
- Prior art keywords
- phenyl
- trifluoromethyl
- optically active
- piperazinyl
- methyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- OHQHTOXXVWBNOL-UHFFFAOYSA-N 3-[(2-piperazin-1-ylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]pyrrolidin-2-one Chemical class C1=CC(C(F)(F)F)=CC=C1N1C(=O)C(CC=2C(=CC=CC=2)N2CCNCC2)CC1 OHQHTOXXVWBNOL-UHFFFAOYSA-N 0.000 title 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 title 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17343799P | 1999-12-29 | 1999-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1113015T3 true DK1113015T3 (da) | 2004-12-13 |
Family
ID=22632024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00311130T DK1113015T3 (da) | 1999-12-29 | 2000-12-13 | Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20010039280A1 (da) |
| EP (1) | EP1113015B1 (da) |
| JP (1) | JP3495708B2 (da) |
| AT (1) | ATE276249T1 (da) |
| CA (1) | CA2329576A1 (da) |
| DE (1) | DE60013751T2 (da) |
| DK (1) | DK1113015T3 (da) |
| ES (1) | ES2225031T3 (da) |
| PT (1) | PT1113015E (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1497265B1 (en) * | 2002-04-19 | 2009-02-18 | Glaxo Group Limited | Compounds having affinity at 5ht2c receptor and use thereof in therapy |
| EP1737466A1 (en) * | 2004-01-29 | 2007-01-03 | Pfizer Products Inc. | COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS |
| ATE521591T1 (de) | 2005-01-13 | 2011-09-15 | Ge Healthcare Ltd | 11c-markierte benzyl-lactam-verbindungen und deren verwendung als bildgebungsmittel |
| JPWO2006104280A1 (ja) * | 2005-03-31 | 2008-09-11 | 武田薬品工業株式会社 | 糖尿病の予防・治療剤 |
| WO2007012964A1 (en) * | 2005-07-25 | 2007-02-01 | Pfizer Products Inc. | Preparation of alkylpiperazinylphenyl compounds by classical resolution |
| WO2007026224A2 (en) * | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | 5-ht1b antagonist composition for depression, anxiety and cognition |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU652759B2 (en) * | 1990-06-01 | 1994-09-08 | Aventisub Ii Inc. | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
| FR2670491B1 (fr) * | 1990-12-14 | 1993-02-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| FR2692264B1 (fr) * | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| TR199801929T2 (xx) * | 1996-03-29 | 1998-12-21 | Pfizer Inc. | Benzil(iden)-laktam t�revleri, bunlar�n 5-HT1A resept�rlerinin (ant)agonistler olarak kullan�mlar� . |
-
2000
- 2000-12-13 DK DK00311130T patent/DK1113015T3/da active
- 2000-12-13 AT AT00311130T patent/ATE276249T1/de not_active IP Right Cessation
- 2000-12-13 DE DE60013751T patent/DE60013751T2/de not_active Expired - Fee Related
- 2000-12-13 ES ES00311130T patent/ES2225031T3/es not_active Expired - Lifetime
- 2000-12-13 EP EP00311130A patent/EP1113015B1/en not_active Expired - Lifetime
- 2000-12-13 PT PT00311130T patent/PT1113015E/pt unknown
- 2000-12-19 US US09/740,361 patent/US20010039280A1/en not_active Abandoned
- 2000-12-27 CA CA002329576A patent/CA2329576A1/en not_active Abandoned
-
2001
- 2001-01-04 JP JP2001000227A patent/JP3495708B2/ja not_active Expired - Fee Related
-
2002
- 2002-08-09 US US10/215,910 patent/US20030083337A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1113015B1 (en) | 2004-09-15 |
| EP1113015A4 (en) | 2001-03-23 |
| ES2225031T3 (es) | 2005-03-16 |
| EP1113015A1 (en) | 2001-07-04 |
| JP3495708B2 (ja) | 2004-02-09 |
| US20030083337A1 (en) | 2003-05-01 |
| PT1113015E (pt) | 2004-12-31 |
| JP2001187781A (ja) | 2001-07-10 |
| US20010039280A1 (en) | 2001-11-08 |
| CA2329576A1 (en) | 2001-06-29 |
| DE60013751D1 (de) | 2004-10-21 |
| DE60013751T2 (de) | 2005-09-29 |
| ATE276249T1 (de) | 2004-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008110984A5 (da) | ||
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| NO20071560L (no) | Vasopressin v1a-antagonister. | |
| CA2252898A1 (en) | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist | |
| SE0302760D0 (sv) | New compounds | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| MA27779A1 (fr) | FORME CRISTALLINE D'AGONISTE DE RECEPTEUR β2 ADRENERGIQUE | |
| NO20042844L (no) | 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister | |
| SG164283A1 (en) | New benzimidazole derivatives | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| MA28435B1 (fr) | Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 | |
| WO2001023357A3 (en) | Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| DK1551803T3 (da) | Azabicycloderivater som muskarine receptorantagonister | |
| DK1113015T3 (da) | Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister | |
| WO2006038006A3 (en) | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders | |
| WO2005092307A3 (en) | Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists | |
| MA26541A1 (fr) | Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines | |
| WO2007067875A3 (en) | Pyridinyl sulfonamide modulators of chemokine receptors | |
| NO20014855D0 (no) | N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister | |
| SE0002729D0 (sv) | Novel compound form | |
| SE9903995D0 (sv) | New combination | |
| TW200519102A (en) | Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors | |
| CA2428511A1 (en) | Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors | |
| SE9900190D0 (sv) | New compounds |